trending Market Intelligence /marketintelligence/en/news-insights/trending/WRgKhyhRPBTM1Mwpalqe1w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Fennec Pharmaceuticals closes $7.6M private placement of common shares

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Fennec Pharmaceuticals closes $7.6M private placement of common shares

Fennec Pharmaceuticals Inc. completed a nonbrokered private placement of 1.9 million common shares, priced $4.00 apiece, for gross proceeds of $7.6 million.

The placement was led by venBio Select Advisor LLC and included existing and new investors.

The company plans to use net proceeds for the development of sodium thiosulfate, or STS, and for general working capital purposes. The company is studying potential benefits of STS in pediatric cancer patients.

In connection with the placement, Essetifin SpA bought an additional 300,000 shares, increasing its stake in Fennec to 2,931,579 shares.

Prior to the offering, the company had 13,707,306 outstanding shares.

The shares issued are subject to a hold period, which will expire four months plus one day from the closing date.